Although there is no direct evidence of clinical complications so far, possible long-term consequences of the anti-GM-CSF responses, such as involvement in pulmonary alveolar proteinosis (PAP) [45,46], are difficult to exclude. Here, CSF2 is linked to pulmonary alveolar proteinosis.